Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor Positive，HER2-negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT04732598
What this trial is testing

A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer

Who this might be right for
Breast Cancer
Japanese Foundation for Cancer Research 281
Large-scale testing (Phase 3)Active Not RecruitingNCT06144944
What this trial is testing

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

Who this might be right for
Breast Cancer InvasiveHormone-receptor-positive Breast CancerHER2 Low Breast Carcinoma+1 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 160
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05986071
What this trial is testing

I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers

Who this might be right for
Breast Cancer
Institut Paoli-Calmettes 57
Large-scale testing (Phase 3)Looking for participantsNCT05827081
What this trial is testing

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Who this might be right for
Early Breast Cancer
Novartis Pharmaceuticals 1,400
Not applicableUnknownNCT05559528
What this trial is testing

BRaziLian outcomE for metAStatic breasT Cancer

Who this might be right for
Metastatic Breast CancerBreast Cancer Stage IV
Hospital do Coracao 300
Not applicableNot Yet RecruitingNCT06810492
What this trial is testing

The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment

Who this might be right for
Breast Cancer Stage IIIBreast Cancer Stage II
Hongmei Zheng, PhD 40
Large-scale testing (Phase 3)Looking for participantsNCT05901428
What this trial is testing

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast Cancer
Fudan University 1,736
Testing effectiveness (Phase 2)Study completedNCT00618657
What this trial is testing

Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting

Who this might be right for
Breast CancerHER2-negative Breast CancerHER2-positive Breast Cancer+7 more
University of California, Irvine 127
Large-scale testing (Phase 3)Active Not RecruitingNCT04906395
What this trial is testing

Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

Who this might be right for
Breast Cancer
Tolmar Inc. 250
Early research (Phase 1)Active Not RecruitingNCT03939897
What this trial is testing

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic HER2-Negative Breast Carcinoma+2 more
National Cancer Institute (NCI) 24
Testing effectiveness (Phase 2)Looking for participantsNCT06923527
What this trial is testing

Circulating Tumor DNA

Who this might be right for
ER+ Breast Cancer
Yale University 50
Testing effectiveness (Phase 2)Study completedNCT02441946
What this trial is testing

A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

Who this might be right for
Breast CancerHormone Receptor Positive TumorEarly-Stage Breast Carcinoma
Eli Lilly and Company 224
Testing effectiveness (Phase 2)Study completedNCT02258451
What this trial is testing

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Bayer 283
Testing effectiveness (Phase 2)Looking for participantsNCT05594095
What this trial is testing

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Who this might be right for
Breast NeoplasmBreast CancerHormone Receptor Positive Tumor+2 more
Fudan University 620
Post-approval studies (Phase 4)WithdrawnNCT03988114
What this trial is testing

Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company
Testing effectiveness (Phase 2)Active Not RecruitingNCT05558722
What this trial is testing

Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer

Who this might be right for
Breast Cancer Stage II
Xijing Hospital 31
Testing effectiveness (Phase 2)Study completedNCT03481998
What this trial is testing

SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 104
Testing effectiveness (Phase 2)Looking for participantsNCT06201234
What this trial is testing

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast CancerAdvanced or Metastatic Breast CancerBRCA1 Mutation+1 more
GBG Forschungs GmbH 176
Testing effectiveness (Phase 2)Looking for participantsNCT06369285
What this trial is testing

Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast CancerMetastatic Breast CancerRecurrent Breast Cancer
Puma Biotechnology, Inc. 225
Not applicableApproved For MarketingNCT02792725
What this trial is testing

Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company
Next Page